Hepatitis C and Senior Citizens  

What happens when the Hepatitis C virus is found in someone who is a senior citizen? First of all its not always easy to diagnose Hepatitis C virus, HCV, because so many of the symptoms, aches and pains in the joints, skin problems, stomach discomforts and memory issues, are what many expect to suffer as they age. But, in truth, if you are a senior you shouldn't expect to feel ill all the time and if you do you should go see your health care provider.

There are some things you should do if you've been diagnosed. First ask for a second test to reconfirm the results. This is just common sense and your doctor won't object. If they do, find another. It's a good idea to get vaccinated against Hepatitis A and B.  Ask to be sent to a specialist who can deal better with your new set of circumstances. This specialist should be prepared to do an alpha-fetoprotein test. This checks for cancer. As well, you should have a liver biopsy to see if there are signs of cirrhosis. 

 You should be cautious in some things that you do to do your best not to be contagious to anyone. This includes not sharing a toothbrush, razor or nail clippers. Avoid risky contact such as allowing your blood to touch someone else's open cut. You can hug, cuddle and kiss your children and grandchildren, but avoid kissing them on the mouth. There is no reason to refrain from continuing the normal healthy sexual relationship you have with your long-term partner.

After you clean your teeth, wash the sink. Using a water and bleach solution, clean and wipe out the sink after each time you clean your teeth. If you cut yourself and there is blood on the counter or floor, be certain that only you clean it up once you've tended to the cut. Throw all paper towels or wipes in a plastic bag and then into the garbage.

The biggest question asked by anyone, let alone someone in their retirement years, is will they die from the Hepatitis c virus?  The answer is only maybe. Studies have shown that most people who become infected after they have passed through middle age usually die from other causes or from old age before the HCV gets them. That is because HCV often stays in a person's system for years, lying dormant, before any of the damage begins.  Cirrhosis of the liver will occur in approximately thirty percent of all HCV sufferers. This in itself can take thirty years to become a health issue.  A percentage of those with cirrhosis of the liver will get liver cancer. But again, this does not develop quickly.

Your doctor may want to discuss with you whether treatment is a good idea or not.  The most commonly used medication for HCV is interferon. This drug has not proven good when used for older patients. It is more common not to treat those over sixty.

Hepatitis news on the Web

As death nears, hepatitis C victim to give videotaped deposition in Desai case - Las Vegas Review-Journal

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience - Wall Street Journal

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes
BioLineRx signs licensing deal with Genoscience, RFS PharmaPharmaceutical Business Review

all 25 news articles »

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ... - FierceBiotech

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

Gilead Sciences Jumps on Hepatitis C Data - Pharmaceutical Processing

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Gilead stock rises on potential hepatitis C cureSan Francisco Business Times (blog)
Proactive Investors USA & Canada -Seeking Alpha -CNBC.com
all 12 news articles »

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Up 6% After Positive Hep-C TrialWall St. Cheat Sheet
DailyFinance -24/7 Wall St.
all 63 news articles »

Culture: Impact of war on language (155) - Egyptian Gazette

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
PR Newswire (press release)
all 31 news articles »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C PillBloomberg
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
LocalizedUSA -Financial News Network Online
all 15 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge

all 5 news articles »

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ... - Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ...
Gastroenterology & Endoscopy News
by Christina Frangou A combination therapy including two investigational direct-acting antiviral agents (DAAs)—asunaprevir and daclatasvir—suppressed hepatitis C virus (HCV) genotype 1 infection in a majority of patients who had previously not ...


Google News